Takeda teams with enGene for gastrointestinal R&D

Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. Under the agreement, enGene will develop two treatments matching up to Takeda-selected targets through preclinical studies, and the major drugmaker will take the reins from there, promising its partner an upfront payment and milestones tied to R&D. Release

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i